Is sclerostin antibody an effective agent for alveolar bone regeneration in animal models? A scoping review
Objectives The use of Sclerostin Antibody(Scl-Ab) as a bone anabolic agent has shown significant benefit in bone disorders in preclinical animal models and human clinical trials. Currently available evidence on the use of Scl-Ab in alveolar bone regeneration is limited to animal studies and hence th...
Main Authors: | Venkitachalam Ramanarayanan, Jothi M Varghese, Madhurya N Kedlaya, Sunaina Banu, Lakshmi Puzhankara |
---|---|
Format: | Article |
Language: | English |
Published: |
Cumhuriyet University
2022-12-01
|
Series: | Cumhuriyet Dental Journal |
Subjects: | |
Online Access: | https://dergipark.org.tr/tr/download/article-file/2403031 |
Similar Items
-
Sclerostin Modulation Holds Promise for Dental Indications
by: Mohamed G. Hassan, et al.
Published: (2018-11-01) -
Drug discovery of sclerostin inhibitors
by: Sifan Yu, et al.
Published: (2022-05-01) -
Antitumor Effect of Sclerostin against Osteosarcoma
by: Hirokazu Ideta, et al.
Published: (2021-11-01) -
Serum sclerostin in vascular calcification in CKD: a meta-analysis
by: Yan Lin, et al.
Published: (2023-12-01) -
Sclerostin antibodies as novel anabolic therapy for osteoporosis
by: Elizaveta O. Mamedova, et al.
Published: (2019-04-01)